Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 261 to 270 of 1514 total matches.
Podofilox For Genital Warts
The Medical Letter on Drugs and Therapeutics • Dec 13, 1991 (Issue 859)
, 77:735, 1991).
The Medical Letter, Vol. 33 (Issue 859) December 13, 1991, pp. 117-118
Copyright ...
Podofilox 0.5% solution (Condylox - Oclassen) was recently approved by the US Food and Drug Administration for treatment of (condylomata acuminata). The drug requires a prescription, but is labeled for application by the patient. Similar topical solutions previously available for this indication are approved only for application by the physician.
Quinapril for Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 20, 1992 (Issue 866)
not
The Medical Letter, Vol. 34 (Issue 866) March 20, 1992, pp. 27-28
Copyright The Medical Letter ...
Quinapril (Accupril - Parke-Davis), an angiotensin-converting enzyme (ACE) inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of hypertension. ACE inhibitors are now widely used for this indication (Medical Letter, 33:33, 1991).
Pravastatin, Simvastatin, and Lovastatin For Serum Cholesterol Concentrations
The Medical Letter on Drugs and Therapeutics • Jun 12, 1992 (Issue 872)
, and
The Medical Letter, Vol. 34 (Issue 872) June 12, 1992, pp. 57-58
Copyright The Medical Letter
UNAUTHORIZED ...
Pravastatin - Bristol-Myers Squibb) and simvastatin (Zocor -Merck), two new inhibitors of cholesterol synthesis similar to lovastatin (Mevacor - Merck), have now been marketed in the USA for treatment of hypercholesterolemia. Lovastatin (Medical Letter, 29:99, 1987) is the most frequently prescribed of all cholesterol-lowering drugs in the USA. Pravastatin and simvastatin were previously reviewed in The Medical Letter when they became available in Canada (volume 33, page 18, 1991).
Flosequinan for Heart Failure
The Medical Letter on Drugs and Therapeutics • Mar 19, 1993 (Issue 892)
. Tachycardia is also common, and hypotension can occur.
The Medical Letter, Vol. 35 (Issue 892) March 19, 1993 ...
Flosequinan (Manoplax - Boots), a fluoroquinolone derivative, is now available in the USA for treatment of congestive heart failure. Labeling approved by the US Food and Drug Administration recommends the drug only for patients who cannot tolerate or have not responded adequately to an angiotensin-converting enzyme (ACE) inhibitor.
Atovaquone for Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Apr 02, 1993 (Issue 893)
, and dizziness.
The Medical Letter, Vol. 35 (Issue 893) April 2, 1993, pp. 28-29
Copyright The Medical Letter ...
Atovaquone (Mepron - Burroughs Wellcome), a hydroxynaphthoquinone, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who cannot tolerate trimethoprim-sulfamethoxazole (Septra, Bactrim, and others). PCP is a common opportunistic infection and frequent cause of death in patients with AIDS.
Nedocromil for Asthma
The Medical Letter on Drugs and Therapeutics • Jul 09, 1993 (Issue 900)
asthma.
The Medical Letter, Vol. 35 (Issue 900) July 9, 1993, pp. 62-63
Copyright The Medical Letter ...
Nedocromil sodium (Tilade - Fisons), an anti-inflammatory drug similar to cromolyn sodium (Intal - Fisons), although chemically unrelated, is now available in the USA as a metered-dose inhaler for maintenance treatment of mild to moderate asthma.
Ketorolac for Seasonal Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Sep 17, 1993 (Issue 905)
of the
The Medical Letter, Vol. 35 (Issue 905) September 17, 1993, pp. 88-89
Copyright The Medical Letter ...
Ketorolac (kee' toe role ak) tromethamine 0.5%, a nonsteroidal anti-inflammatory drug (NSAID) previously available for parenteral and oral administration (Toradol - Medical Letter, 32:79, 1990), has now been approved for ophthalmic use (Acular - Allergan, Fisons) to relieve itching in seasonal allergic conjunctivitis. NSAIDs decrease prostaglandin concentrations in the eye, which theoretically might contribute to a decrease in itching. Several other NSAIDs are available for ophthalmic use in the USA, but none is marketed for this indication. Flurbiprofen (Ocufen) and suprofen (Profenal) ...
Tetramune - A Combined Vaccine For Infants
The Medical Letter on Drugs and Therapeutics • Nov 12, 1993 (Issue 909)
.
(continued on next page)
The Medical Letter, Vol. 35 (Issue 909) November 12, 1993, pp. 104-105
Copyright ...
The number of immunizations recommended for infants and young children has increased in recent years with the addition of vaccines to prevent Haemophilus influenzae type b infection and hepatitis B (Medical Letter, 33:5, 1991; 34:69, 1992). Now the US Food and Drug Administration has licensed a new vaccine for infants (Tetramune - Lederle-Praxis) that combines a traditional diphtheria, tetanus, and pertussis vaccine (DTP; Tri-Immunol) with a vaccine against Haemophilus influenzae type b (HibTiter).
Butorphanol Nasal Spray for Pain
The Medical Letter on Drugs and Therapeutics • Nov 12, 1993 (Issue 909)
), a similar drug, have also occurred with intranasal butorphanol (L
The Medical Letter, Vol. 35 (Issue 909 ...
Butorphanol tartrate, a synthetic opioid agonist-antagonist analgesic previously available for injection, is now being marketed as a nasal spray (Stadol-NS - Mead Johnson). The spray was approved by the US Food and Drug Administration (FDA) for any type of pain for which an opioid analgesic is appropriate, but the manufacturer is emphasizing use for treatment of migraine headache and postoperative pain. Drugs for pain were reviewed in the Medical Letter, volume 35, page 1, January 8, 1993.
Terazosin for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • Feb 18, 1994 (Issue 916)
be taken at bedtime. Patients with nocturia, which
The Medical Letter, Vol. 36 (Issue 916) February 18 ...
Terazosin (Hytrin - Abbott), a postsynaptic alpha 1 -adrenoreceptor blocker previ-ously available for treatment of hypertension (Medical Letter, 29:113, 1987), has now been approved by the US Food and Drug Administration (FDA) for treatment of benign prostatic hyperplasia (BPH). Although not previously approved by the FDA, terazosin and other alpha-blockers such as prazosin (Minipress, and others) or doxazosin (Car-dura) have been used for this indication for many years.